Stock Market Reviews

LTRN (Lantern Pharma Inc.) News

Get the latest news, insights, and market updates on LTRN (Lantern Pharma Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
  DALLAS, November 06, 2025--Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
  Nov 6, 2025 - $LTRN
• Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT
  DALLAS, October 30, 2025--Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT.
  Oct 30, 2025 - $LTRN
• Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.
  DALLAS, October 28, 2025--LP-284 at 25th LL&M Congress & CMR
  Oct 28, 2025 - $LTRN
• Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025
  DALLAS, October 24, 2025--Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025
  Oct 24, 2025 - $LTRN
• Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
  ORLANDO, FLORIDA / ACCESS Newswire / October 3, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Lantern Pharma, Inc. (Nasdaq:LTRN) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg ...
  Oct 3, 2025 - $LTRN
• Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors
  DALLAS, September 16, 2025--Clinical Trial Results, LP-184
  Sep 16, 2025 - $LTRN
• IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)
  AUSTIN, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancem
  Sep 10, 2025 - $LTRN
• Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development
  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced that it is leveraging Lantern Pharma's breakthrough PredictBBB.ai™ platform, a next-generation artificial intelligence (AI) tool with 94% accuracy in predicting blood-brain barrier permeability. This adoption positions Hoth at the forefront of AI-driven drug development, reinforcing its commitment to cutting-edge innovation and accelerated therapeutic discovery.
  Sep 4, 2025 - $LTRN
• Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial
  DALLAS, September 03, 2025--Type C Meeting for LP-184/STAR-001
  Sep 3, 2025 - $LTRN
• RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26
  ORLANDO, FLORIDA / ACCESS Newswire / August 19, 2025 / RedChip Companies, an international investor relations, media, and research firm focused on microcap and small-cap companies, will host an exclusive live investor webinar with Lantern Pharma Inc. ...
  Aug 19, 2025 - $LTRN